Gentamicin therapy for sepsis due to carbapenem-resistant and colistin-resistant Klebsiella pneumoniae | Zendy

Marcelino González-Padilla | Zendy; Julián TorreCisneros | Zendy; F. Rivera-Espinar | Zendy; Antonio Pontes-Moreno | Zendy; Lorena LópezCerero | Zendy; Álvaro Pascual | Zendy; C. Natera | Zendy; Miguel Ángel Morán Rodríguez | Zendy; Inmaculada Salcedo-Leal | Zendy; Fernando Rodríguez-López | Zendy; Antonio Rivero | Zendy; Jesús RodríguezBaño | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Gentamicin therapy for sepsis due to carbapenem-resistant and colistin-resistant Klebsiella pneumoniae

Author(s) -

Marcelino González-Padilla,

Julián TorreCisneros,

F. Rivera-Espinar,

Antonio Pontes-Moreno,

Lorena LópezCerero,

Álvaro Pascual,

C. Natera,

Miguel Ángel Morán Rodríguez,

Inmaculada Salcedo-Leal,

Fernando Rodríguez-López,

Antonio Rivero,

Jesús RodríguezBaño

Publication year - 2014

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dku432

Subject(s) - klebsiella pneumoniae , colistin , medicine , gentamicin , tigecycline , carbapenem , proportional hazards model , sepsis , mortality rate , retrospective cohort study , microbiology and biotechnology , biology , antibiotics , biochemistry , escherichia coli , gene

Antimicrobial therapy for sepsis caused by carbapenem- and colistin-resistant Klebsiella pneumoniae is not well established. We hypothesized that the early use of gentamicin in cases due to susceptible organisms would decrease the crude mortality rate of this infection.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research